© Brighteon.com All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. Brighteon is not responsible for comments and content uploaded by our users.
This channel has partnered with the Brighteon Store and receives a small commission from all sales generated from an affiliate link.
Click the shop now button below to help out this channel.
Swiss health economist prof. dr. Konstantin Beck (University of Lucerne) [1] discusses data provided by major Swiss health insurer Helsana [2] about the number of their patients who receive cancer drugs. The latest update has been published on November 30th, 2023.
The average of the number from 2013-2020 is 92 451. In 2022, this number of Helsana insured who were on cancer drugs SUDDENLY increased to at least 152 000, which is an increase of 64%. The increase is 94% compared to 2017.
REFERENCES
[1] Prof. dr. Konstantin Beck (University of Lucerne)
[2] Health insurer Helsana
https://en.wikipedia.org/wiki/Helsana
SOURCES
Original video (without subtitles):
https://www.youtube.com/watch?v=3Z6rviCbCNg
Tweet by aussie17, who added subtitels:
https://twitter.com/_aussie17/status/1732563320304193921
Mirrored - frankploegman
FDA escalates recall of blood pressure drug amid carcinogen concerns—yet another failure in Big Pharma’s toxic empire
CIA’s Cold War Tick Experiments Examined Following New Allegations Linking Them to Lyme Outbreak
Analysis of Liver Detox Diet Claims: Scientific Review and Expert Perspectives
The longevity molecule: How a common amino acid could rewrite the rules of aging
Study Reviews Potential Immune System Effects of Green Tea Consumption
Corn: A nutritious staple or hidden health risk?
